Biotech | May 08, 2022
Oncocyte completes validation of Therasure transplant monitor test
Digital PCR format allows for rapid turnaround time to facilitate fast and accurate post-transplant treatment decisions
Digital PCR format allows for rapid turnaround time to facilitate fast and accurate post-transplant treatment decisions
By connecting a leading LongBio VC to the DeSci (decentralized science) movement, this partnership is a major milestone for the greater decentralized ecosystem
BDR Pharmaceuticals is a home-grown company with operations in India and overseas. It’s known for its formulations portfolio and has a presence in specialty medicines. The company has ambitious plans as it has ramped up capacity and looking to foray into regulated markets. Raheel Shah, Director, BDR Group of Companies shares his insights in an interview with Thomas C Thottathil, Editor, Indian Pharma Post
The company has enabled a transformation across three core areas with an investment target of US $ 150 million
The company's discovery services support a wide range of global innovator companies from start-ups to large pharma companies, across a diverse set of therapeutic areas including oncology, CNS, antivirals, and inflammation among others
The company reported total income of Rs.1215.73 crores during the period ended June 30, 2021.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
